Bladder cancer is the fourth leading cause of cancer in men and the eight in women.
Bladder cancer is considered the cancer with the highest cost per single patient from diagnosis to death and
the fifth most expensive cancer in terms of total
medical care expenditures, accounting in the US alone around 4 billion dollars due
to the long-term survival rate and the need for lifelong routine monitoring and
treatment.
TheraCoat Ltd. is a medical application company developing biodegradable drug delivery
systems for a local treatment in internal cavities. TheraCoat first application is a slow release
chemotherapy intravesical instillation for Superficial Bladder Cancer.
|
|
|
|
 |
